Targeting THOC2-Mediated mRNA Export Induces PARP Inhibitor Vulnerability in DNA Repair-Competent Hepatocellular

Xinli Li1, Songpeng Yang1, Mengxin Zhang1

  • 1State Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Beijing 102206, China.

Insights

THOC2 regulates DNA damage response (DDR) by controlling mRNA export. Targeting THOC2 with Poly (ADP-ribose) polymerase inhibitors (PARPi) shows promise for treating hepatocellular carcinoma (HCC) by inducing synthetic lethality.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Hepatocellular carcinoma (HCC) presents limited therapeutic options due to low mutation rates in DNA repair genes.
  • Poly (ADP-ribose) polymerase inhibitors (PARPi) are effective in tumors with DNA repair defects, but their utility in HCC is restricted.
  • Enhanced DNA repair capacity in HCC limits the efficacy of conventional treatments.

Purpose of the Study:

  • To identify novel regulators of DNA damage response (DDR) in hepatocellular carcinoma (HCC).
  • To investigate the role of THO complex component 2 (THOC2) in DDR and its potential as a therapeutic target.
  • To explore strategies for overcoming PARPi resistance in HCC.

Main Methods:

  • Proteomic analysis of two independent HCC cohorts (n=260).
  • Investigated THOC2's role in mRNA nuclear export of DDR and proliferation-related genes.
  • Assessed the synergistic effect of THOC2 knockdown and PARPi (Olaparib) on HCC cell lines and tumor growth.

Main Results:

  • THOC2 was identified as a master regulator of DDR through mRNA nuclear export control.
  • THOC2 overexpression correlated with poor HCC patient survival and increased DDR gene expression.
  • THOC2 knockdown induced synthetic lethality with PARPi, significantly reducing Olaparib efficacy and suppressing tumor growth.

Conclusions:

  • THOC2 is a prognostic biomarker and therapeutic target for hepatocellular carcinoma (HCC).
  • Targeting mRNA transport offers a novel strategy to modulate DDR and overcome PARPi resistance.
  • This study expands the concept of synthetic lethality beyond genetic defects to include post-transcriptional regulation in cancer therapy.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...